Cerula Care Targets Growth Opportunity in Collaborative Oncology Care

According to a recent LinkedIn post from Cerula Care, a new JAMA Network analysis is cited as showing rapid growth in the use of the Collaborative Care Model, or CoCM, within Medicare. The post indicates that adoption in oncology settings is growing but still trails what the company views as the model’s potential in cancer care.

The LinkedIn post argues that oncology is well suited to collaborative care because cancer treatment is already multidisciplinary and can integrate behavioral health into existing workflows. It also notes that CoCM is designed to use measurement‑based care and extend limited psychiatric expertise, which is presented as supporting better access and outcomes in “whole‑person” oncology care.

Cerula Care’s post highlights a sharp rise in oncology CoCM services from 2022 to 2024, describing this as both momentum and a sign of remaining opportunity in the market. For investors, this trend, if sustained, could imply expanding demand for care coordination and behavioral health integration solutions focused on oncology populations.

The post references Cerula Care’s work with several oncology groups, including The US Oncology Network, Virginia Oncology Associates, and Maryland Oncology Hematology, as examples of current collaborations. It also acknowledges other organizations in the space, such as OneOncology, American Oncology Network, Adjuvant Behavioral Health, Colla Health, and Protocol Behavioral Health, underscoring a competitive yet growing ecosystem.

From an investment perspective, the emphasis on scaling CoCM in oncology suggests a potential long‑term revenue opportunity tied to value‑based care and Medicare‑reimbursed behavioral health services. If Cerula Care can deepen its partnerships and demonstrate measurable clinical and economic benefits, it may strengthen its positioning within a niche but expanding segment of oncology support services.

At the same time, the mention of multiple peers indicates that barriers to entry may be moderate and that differentiation will likely depend on outcomes data, integration capabilities, and payer alignment. Investors may therefore watch for further evidence of adoption, contract wins, and reimbursement stability as key indicators of Cerula Care’s ability to capture share in collaborative oncology care.